Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Correction: Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel.

McDonald JT, Kritharis A, Beheshti A, Pilichowska M, Burgess K, Ricks-Santi L, McNiel E, London CA, Ravi D, Evens AM.

Oncotarget. 2018 Sep 7;9(70):33441. doi: 10.18632/oncotarget.26114. eCollection 2018 Sep 7.

2.

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.

London CA, Acquaviva J, Smith DL, Sequeira M, Ogawa LS, Gardner HL, Bernabe LF, Bear MD, Bechtel SA, Proia DA.

Clin Cancer Res. 2018 Aug 31. doi: 10.1158/1078-0432.CCR-18-0703. [Epub ahead of print]

PMID:
30171047
3.

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.

Sadowski AR, Gardner HL, Borgatti A, Wilson H, Vail DM, Lachowicz J, Manley C, Turner A, Klein MK, Waite A, Sahora A, London CA.

BMC Vet Res. 2018 Aug 24;14(1):250. doi: 10.1186/s12917-018-1587-9.

4.

IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.

Gross AC, Cam H, Phelps DA, Saraf AJ, Bid HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, Mo X, Hinckley JM, Houghton PJ, Roberts RD.

JCI Insight. 2018 Aug 23;3(16). pii: 99791. doi: 10.1172/jci.insight.99791. [Epub ahead of print]

5.

Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.

Gardner HL, Rippy SB, Bear MD, Cronin KL, Heeb H, Burr H, Cannon CM, Penmetsa KV, Viswanadha S, Vakkalanka S, London CA.

PLoS One. 2018 Apr 24;13(4):e0195357. doi: 10.1371/journal.pone.0195357. eCollection 2018.

6.

Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.

Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd.

Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.

PMID:
29622581
7.

MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines.

Lopez CM, Yu PY, Zhang X, Yilmaz AS, London CA, Fenger JM.

PLoS One. 2018 Jan 2;13(1):e0190086. doi: 10.1371/journal.pone.0190086. eCollection 2018.

8.

c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.

Weishaar KM, Ehrhart EJ, Avery AC, Charles JB, Elmslie RE, Vail DM, London CA, Clifford CA, Eickhoff JC, Thamm DH.

J Vet Intern Med. 2018 Jan;32(1):394-405. doi: 10.1111/jvim.14889. Epub 2017 Nov 30.

9.

Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia.

Schuh EM, Portela R, Gardner HL, Schoen C, London CA.

BMC Vet Res. 2017 Oct 2;13(1):294. doi: 10.1186/s12917-017-1209-y.

10.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA.

PLoS One. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017.

11.

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

Laver T, London CA, Vail DM, Biller BJ, Coy J, Thamm DH.

Vet Comp Oncol. 2018 Mar;16(1):E23-E29. doi: 10.1111/vco.12328. Epub 2017 Jun 15.

PMID:
28621057
12.

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.

Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC.

BMC Cancer. 2017 Jan 21;17(1):67. doi: 10.1186/s12885-017-3046-6.

13.

Erratum to: A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.

Rippy SB, Gardner HL, Nguyen SM, Warry EE, Portela RF, Drost WT, Hostnik ET, Green EM, Chew DJ, Peng J, London CA.

BMC Vet Res. 2016 Dec 30;12(1):291. doi: 10.1186/s12917-016-0934-y. No abstract available.

14.

Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species.

Lundberg AP, Francis JM, Pajak M, Parkinson EI, Wycislo KL, Rosol TJ, Brown ME, London CA, Dirikolu L, Hergenrother PJ, Fan TM.

Invest New Drugs. 2017 Apr;35(2):134-144. doi: 10.1007/s10637-016-0414-z. Epub 2016 Dec 14.

PMID:
27975234
15.

A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.

Rippy SB, Gardner HL, Nguyen SM, Warry EE, Portela RA, Drost WT, Hostnik ET, Green EM, Chew DJ, Peng J, London CA.

BMC Vet Res. 2016 Nov 17;12(1):257. Erratum in: BMC Vet Res. 2016 Dec 30;12 (1):291.

16.

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R.

Clin Cancer Res. 2017 May 15;23(10):2565-2574. doi: 10.1158/1078-0432.CCR-16-2152. Epub 2016 Nov 4.

17.

MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.

Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI, Modiano JF, Kisseberth WC, London CA.

BMC Cancer. 2016 Oct 10;16(1):784.

18.

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.

Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC.

PLoS One. 2016 Jul 19;11(7):e0159607. doi: 10.1371/journal.pone.0159607. eCollection 2016.

19.

ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma.

Cam M, Gardner HL, Roberts RD, Fenger JM, Guttridge DC, London CA, Cam H.

Oncotarget. 2016 Jul 26;7(30):48533-48546. doi: 10.18632/oncotarget.10406.

20.

Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

Mani R, Yan R, Mo X, Chen CS, Phelps MA, Klisovic R, Byrd JC, Kisseberth WC, London CA, Muthusamy N.

Vet Comp Oncol. 2017 Sep;15(3):1115-1118. doi: 10.1111/vco.12221. Epub 2016 May 2.

21.

Dogs as a Model for Cancer.

Gardner HL, Fenger JM, London CA.

Annu Rev Anim Biosci. 2016;4:199-222. doi: 10.1146/annurev-animal-022114-110911. Epub 2015 Nov 9. Review.

PMID:
26566160
22.

Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines.

Clemente-Vicario F, Alvarez CE, Rowell JL, Roy S, London CA, Kisseberth WC, Lorch G.

PLoS One. 2015 Nov 11;10(11):e0142007. doi: 10.1371/journal.pone.0142007. eCollection 2015.

23.

Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma.

Brown ME, Bear MD, Rosol TJ, Premanandan C, Kisseberth WC, London CA.

BMC Vet Res. 2015 Aug 14;11:206. doi: 10.1186/s12917-015-0505-7.

24.
25.

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.

Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD.

BMC Vet Res. 2015 Jun 11;11:131. doi: 10.1186/s12917-015-0446-1.

26.

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.

London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G.

PLoS One. 2015 Apr 29;10(4):e0124889. doi: 10.1371/journal.pone.0124889. eCollection 2015.

27.

Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors.

Hosoya K, Couto CG, London CA, Kisseberth WC, Phelps MA, Dalton JT.

J Am Anim Hosp Assoc. 2014 Nov-Dec;50(6):390-5. doi: 10.5326/JAAHA-MS-6145. Epub 2014 Sep 23.

PMID:
25251432
28.

Small molecule inhibitors in veterinary oncology practice.

London CA.

Vet Clin North Am Small Anim Pract. 2014 Sep;44(5):893-908. doi: 10.1016/j.cvsm.2014.06.001. Epub 2014 Jul 12. Review.

PMID:
25174906
29.

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.

Breit MN, Kisseberth WC, Bear MD, Landesman Y, Kashyap T, McCauley D, Kauffman MG, Shacham S, London CA.

BMC Vet Res. 2014 Jul 15;10:160. doi: 10.1186/1746-6148-10-160.

30.

Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.

Fenger JM, London CA, Kisseberth WC.

ILAR J. 2014;55(1):69-85. doi: 10.1093/ilar/ilu009. Review.

PMID:
24936031
31.

Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis.

Fenger JM, Bear MD, Volinia S, Lin TY, Harrington BK, London CA, Kisseberth WC.

BMC Cancer. 2014 Feb 11;14:84. doi: 10.1186/1471-2407-14-84.

32.

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.

London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR, McCauley D, Kauffman M, Shacham S.

PLoS One. 2014 Feb 4;9(2):e87585. doi: 10.1371/journal.pone.0087585. eCollection 2014.

33.

Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B.

Karlsson EK, Sigurdsson S, Ivansson E, Thomas R, Elvers I, Wright J, Howald C, Tonomura N, Perloski M, Swofford R, Biagi T, Fryc S, Anderson N, Courtay-Cahen C, Youell L, Ricketts SL, Mandlebaum S, Rivera P, von Euler H, Kisseberth WC, London CA, Lander ES, Couto G, Comstock K, Starkey MP, Modiano JF, Breen M, Lindblad-Toh K.

Genome Biol. 2013 Dec 12;14(12):R132. doi: 10.1186/gb-2013-14-12-r132.

34.

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CA.

BMC Vet Res. 2013 Sep 30;9:190. doi: 10.1186/1746-6148-9-190.

35.

miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.

Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC.

Sci Signal. 2013 Jul 30;6(286):ra63. doi: 10.1126/scisignal.2004177. Erratum in: Sci Signal. 2013 Sep 10;6(292):er6. Balkhi, Mumtaz Y [corrected to Balkhi, M Y].

36.

Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.

Martin CK, Dirksen WP, Carlton MM, Lanigan LG, Pillai SP, Werbeck JL, Simmons JK, Hildreth BE 3rd, London CA, Toribio RE, Rosol TJ.

Vet Comp Oncol. 2015 Sep;13(3):203-17. doi: 10.1111/vco.12037. Epub 2013 May 8.

37.

Safety and efficacy field study of artesunate for dogs with non-resectable tumours.

Rutteman GR, Erich SA, Mol JA, Spee B, Grinwis GC, Fleckenstein L, London CA, Efferth T.

Anticancer Res. 2013 May;33(5):1819-27.

PMID:
23645726
38.

Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.

Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ.

Clin Cancer Res. 2013 Jun 1;19(11):2984-94. doi: 10.1158/1078-0432.CCR-12-2008. Epub 2013 Apr 2.

39.

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document.

Nguyen SM, Thamm DH, Vail DM, London CA.

Vet Comp Oncol. 2015 Sep;13(3):176-83. doi: 10.1111/vco.12032. Epub 2013 Mar 28.

PMID:
23534501
40.

Kinase dysfunction and kinase inhibitors.

London CA.

Vet Dermatol. 2013 Feb;24(1):181-7.e39-40. doi: 10.1111/j.1365-3164.2012.01081.x. Review.

PMID:
23331696
41.

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA.

BMC Vet Res. 2012 Dec 17;8:244. doi: 10.1186/1746-6148-8-244.

43.

Retrospective evaluation of the effectiveness of epsilon aminocaproic acid for the prevention of postamputation bleeding in retired racing Greyhounds with appendicular bone tumors: 46 cases (2003-2008).

Marín LM, Iazbik MC, Zaldivar-Lopez S, Lord LK, Stingle N, Vilar P, Lara-Garcia A, Alvarez F, Hosoya K, Nelson L, Pozzi A, Cooper E, McLoughlin MA, Ball R, Kisseberth WC, London CA, Dudley R, Dyce J, McMahon M, Lerche P, Bednarski R, Couto CG.

J Vet Emerg Crit Care (San Antonio). 2012 Jun;22(3):332-40. doi: 10.1111/j.1476-4431.2012.00735.x. Epub 2012 May 21.

PMID:
22612729
44.

Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.

Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ.

PLoS One. 2012;7(4):e35513. doi: 10.1371/journal.pone.0035513. Epub 2012 Apr 17.

45.

Accuracy of computed tomography in determining lesion size in canine appendicular osteosarcoma.

Karnik KS, Samii VF, Weisbrode SE, London CA, Green EM.

Vet Radiol Ultrasound. 2012 May-Jun;53(3):273-9. doi: 10.1111/j.1740-8261.2012.01930.x. Epub 2012 Mar 14.

46.

Met interacts with EGFR and Ron in canine osteosarcoma.

McCleese JK, Bear MD, Kulp SK, Mazcko C, Khanna C, London CA.

Vet Comp Oncol. 2013 Jun;11(2):124-39. doi: 10.1111/j.1476-5829.2011.00309.x. Epub 2011 Dec 8.

47.

Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.

Carlsten KS, London CA, Haney S, Burnett R, Avery AC, Thamm DH.

J Vet Intern Med. 2012 Jan-Feb;26(1):135-41. doi: 10.1111/j.1939-1676.2011.00851.x. Epub 2011 Dec 19.

48.

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.

London CA, Bear MD, McCleese J, Foley KP, Paalangara R, Inoue T, Ying W, Barsoum J.

PLoS One. 2011;6(11):e27018. doi: 10.1371/journal.pone.0027018. Epub 2011 Nov 3.

49.

Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA.

BMC Cancer. 2011 Apr 11;11:125. doi: 10.1186/1471-2407-11-125.

50.

The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.

Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA.

BMC Cancer. 2011 Mar 28;11:112. doi: 10.1186/1471-2407-11-112.

Supplemental Content

Loading ...
Support Center